The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis

[1] Black KE(2007)Fungal infections of the CNS: treatment strategies for the immunocompromised patient CNS Drugs 21 293-318

[2] Baden LR(2007)CNS pharmacokinetics of antifungal agents Expert Opin Drug Metab Toxicol 3 573-581

[3] Kethireddy S(2009)Cerebral aspergillosis: tissue penetration is the key Med Mycol 47 S387-S393

[4] Andes D(2005)Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 2641-2645

[5] Schwartz S(2008)Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients Antimicrob Agents Chemother 52 1743-1750

[6] Thiel E(2002)Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Eng J Med 347 408-415

[7] Schwartz S(2003)Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 1122-1131

[8] Ruhnke M(2002)Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563-571

[9] Ribaud P(2006)Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis Am J Med 119 527.e17-527.e24

[10] Troke P(2008)Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813-1821

[1] Black KE(2007)Fungal infections of the CNS: treatment strategies for the immunocompromised patient CNS Drugs 21 293-318

[2] Baden LR(2007)CNS pharmacokinetics of antifungal agents Expert Opin Drug Metab Toxicol 3 573-581

[3] Kethireddy S(2009)Cerebral aspergillosis: tissue penetration is the key Med Mycol 47 S387-S393

[4] Andes D(2005)Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 2641-2645

[5] Schwartz S(2008)Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients Antimicrob Agents Chemother 52 1743-1750

[6] Thiel E(2002)Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Eng J Med 347 408-415

[7] Schwartz S(2003)Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 1122-1131

[8] Ruhnke M(2002)Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 563-571

[9] Ribaud P(2006)Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis Am J Med 119 527.e17-527.e24

[10] Troke P(2008)Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813-1821